Assessing the Health and Economic Impact of a Potential Menthol Cigarette Ban in New York City: a Modeling Study

Yan Li · Julia Sisti · Karen R. Flórez · Sandra S. Albrecht · Anita Viswanath · Marivel Davila · Jennifer Cantrell · Diksha Brahmbhatt · Azure B. Thompson · John Jasek · Earle C. Chambers

Accepted: 13 October 2021 / Published online: 9 November 2021
© The Author(s) 2021, corrected publication 2021

Abstract Menthol in cigarettes increases nicotine dependence and decreases the chances of successful smoking cessation. In New York City (NYC), nearly half of current smokers usually smoke menthol cigarettes. Female and non-Latino Black individuals were more likely to smoke menthol-flavored cigarettes compared to males and other races and ethnicities. Although the US Food and Drug Administration recently announced that it will ban menthol cigarettes, it is unclear how the policy would affect population health and health disparities in NYC. To inform potential policymaking, we used a microsimulation model of cardiovascular disease (CVD) to project the long-term health and economic impact of a potential menthol ban in NYC. Our model projected that there could be 57,232 (95% CI: 51,967–62,497) myocardial infarction (MI) cases and 52,195 (95% CI: 47,446–56,945) stroke cases per 1 million adult smokers in NYC over a 20-year period without the menthol ban policy. With the menthol ban policy, 2,862 MI cases and 1,983 stroke cases per 1 million adults could be averted over a 20-year period. The model also projected that an average of $1,836 in healthcare costs per person, or $1.62 billion among all adult smokers, could be saved over a 20-year period due to the implementation of a menthol ban policy. Results from subgroup analyses showed that women, particularly Black women, would have more reductions in adverse health outcomes.
CVD outcomes from the potential implementation of the menthol ban policy compared to males and other racial and ethnic subgroups, which implies that the policy could reduce sex and racial and ethnic CVD disparities. Findings from our study provide policymakers with evidence to support policies that limit access to menthol cigarettes and potentially address racial and ethnic disparities in smoking-related disease burden.

Keywords  Tobacco control · Health disparity · Cardiovascular disease · Urban health

Introduction

Smoking is the leading preventable cause of premature death worldwide [1–3] and increases the risk for many adverse health outcomes including cancer, heart disease, stroke, and chronic obstructive pulmonary disease (COPD). [4–6] While overall smoking prevalence has decreased over the past two decades in the United States (US), there has been an increase in menthol cigarette sales and use among current smokers. [7–9] There is strong evidence that menthol in cigarettes increases nicotine dependence and decreases the chance of successful smoking cessation. [7, 10, 11]

Menthol cigarette use is particularly prevalent among females, youth, and people of color in the US, likely due in part to aggressive tobacco industry marketing and promotion to these communities. [7, 12–14] Women are more likely to smoke menthol-flavored cigarettes than men. [13] More than 50% of youth that smoke cigarettes smoke menthol-flavored cigarettes. [15] Almost one-third of current menthol smokers are Black compared to only 3% of non-menthol smokers who are Black. [16] Health advocacy agencies have come out strongly against the sale of flavored cigarettes because of their predominance of use among marginalized populations. [17, 18] The World Health Organization (WHO) recommends banning the use of menthol in cigarettes and other tobacco products in an effort to decrease the prevalence of smoking and improve population health. [19, 20] The US Food and Drug Administration (FDA) also recently announced that it will ban menthol—the last allowable flavor—in cigarettes. [21]

Beginning in January 2017, the province of Ontario, Canada, banned the use of menthol-flavored tobacco products. [22] Evaluation studies of this ban show a significant reduction in the sales of cigarettes in Ontario and an increased rate of quitting among daily and occasional menthol smokers. [22–24] New York City (NYC) has considered implementing a similar policy, building on its ban of non-menthol-flavored tobacco products; [25] legislation was introduced in 2019 but, in the face of opposition, was not put to a vote. [26] Although there is promising evidence of the effectiveness of a menthol cigarette ban, the long-term health and economic costs of these types of cigarette bans are unclear. It is also uncertain whether this ban will have similar effects among groups who experience tobacco-related health disparities, [27] specifically racial and ethnic minorities, a group targeted by the tobacco industry for the sale of menthol cigarettes and known to disproportionately use menthol cigarettes. [14]

To inform policymaking, this study aims to project the long-term health and economic impact of a potential menthol cigarette ban in NYC using a microsimulation model of cardiovascular disease (CVD). We use CVD as the outcome of interest, as it is the leading cause of death in the US and NYC, and smoking is one of the most important risk factors for CVD. [28] In addition, there are stark sex and racial and ethnic disparities in CVD risk factors in NYC and across the country. [29, 30] Since the prevalence of menthol cigarette use varies significantly across different sex and racial and ethnic groups, a second aim is to examine how the potential ban may differentially affect individuals across sex and race and ethnicity, including whether or not the policy would reduce disparities in health outcomes and healthcare costs between groups.

Methods

We developed a microsimulation model of CVD that can be used to project the long-term impact of a public health policy or intervention on CVD health outcomes and healthcare costs. In a microsimulation model, simulated individuals are generated with predefined characteristics (e.g., age, sex, race, ethnicity). Their health behaviors (e.g., smoking, diet) can be modified to understand how such behaviors would
impact health outcomes (e.g., myocardial infarction, stroke) as the simulation runs. By simulating the same group of individuals under different policy scenarios, researchers can compare the impact of different policies and identify the most cost-effective policy in a low-risk “virtual” environment.

Model Structure

The microsimulation model used for this study can project CVD outcomes (i.e., myocardial infarction (MI) and stroke) and healthcare costs among adults in NYC. Figure 1 shows the model schematic design. Specifically, the model can generate a group of adults with a variety of demographic characteristics. We only simulate adult cigarette smokers in this study because the menthol ban policy would primarily affect adults who smoke. Each simulated individual is assigned to be a menthol cigarette smoker or non-menthol cigarette smoker based on a probability that is calculated based on his/her sex and race and ethnicity. As the simulation runs, individuals will age and potentially develop CVD. Finally, the model will calculate the total numbers of MI and stroke and cumulative healthcare costs due to CVD. The model was programmed using simulation software AnyLogic 8.

Parameter Estimation

Publicly available health data are used from various city-based sources to inform our simulation models to estimate and calibrate the model parameters. Specifically, we estimated demographic and health characteristics based on data from the 2013–2014 NYC Health and Nutrition Examination Survey (HANES). The NYC HANES data, a cross-sectional population health survey designed to assess the health of New Yorkers, was used because it includes a range of variables on CVD and its risk factors. It also provides a representative sample of non-institutionalized adults in NYC. Standardized protocols used in NHANES and testing laboratories were used in the NYC HANES to collect data for demographic and health factors.

The CVD risk factors included in the model are age, sex, race, ethnicity, body mass index, systolic blood pressure, LDL-C level, HDL cholesterol level, diabetes, and smoking status. Annual CVD event and CVD-related mortality probabilities were estimated.
using the Cox proportional hazard regression functions (Eq. 1) based on data from a National Heart, Lung, and Blood Institute Pooled Cohort. [35]

\[
P(\text{incidentCVD} = 1) = \frac{\exp(\alpha + \beta_{BM} \cdot BMI + \beta_{LDL-c} \cdot X_{LDL-c} + \cdots + \beta_{sbp} \cdot X_{sbp})}{1 + \exp(\alpha + \beta_{BM} \cdot BMI + \beta_{LDL-c} \cdot X_{LDL-c} + \cdots + \beta_{sbp} \cdot X_{sbp})}
\]

We estimated the prevalence of usual menthol cigarette use among current smokers using data from the 2018 NYC Community Health Survey, a cross-sectional, dual-frame cellphone/landline survey conducted annually by the NYC Department of Health and Mental Hygiene. [36] More specifically, responses to the following question “Thinking about the type of cigarettes you usually smoke, are they menthol or non-menthol?” were used to identify those who usually smoke menthol cigarettes in NYC. We then calculated the prevalence of usual menthol cigarette use across sex (i.e., male, female) and racial and ethnic (i.e., non-Latino White, non-Latino Black, Latino) groups.

If the menthol cigarette ban is to be implemented, the proportion of current menthol smokers who would quit was estimated to be 21.2% based on an evaluation of the menthol cigarette ban policy implemented in the province of Ontario, Canada. [23] The other menthol smokers (78.8%) may switch to non-menthol cigarettes or cigars or purchase menthol cigarettes in other cities where there is no such ban. [37] We used evidence from Ontario because it is the best available real-world evidence on the effect of a menthol cigarette ban, and uncertainty on the parameter estimation was assessed by sensitivity analyses. We also assumed that the menthol ban policy would only affect those who smoke menthol cigarettes, not those who smoke non-menthol cigarettes or did not smoke. This assumption was supported by findings from a recent expert elicitation on the effects of a menthol ban policy in the US. [38]

We estimated healthcare cost parameters based on the Medical Expenditure Panel Survey (MEPS) data. [39] Specifically, every simulated individual accrues annual age-specific “background” cost when he/she has not yet developed CVD. When the simulated individual develops MI or stroke, the specific cost associated with that disease will be added to the total healthcare costs. All healthcare costs were discounted at 3% (a widely accepted discount rate in economic evaluations of health policies) [40] and converted to 2018 dollars. Sensitivity analysis was conducted to assess the impact of different discount rates on healthcare costs.

Simulation Experimental Design

Our study includes two simulation scenarios—implementing the menthol cigarette ban and not implementing the menthol cigarette ban (the status quo). For each of the scenarios, we simulated 10,000 adult smokers and projected the cumulative cases of MI and stroke as well as healthcare costs associated with CVD over a 20-year period (from 2018 to 2038). We calculated the averted cases of MI and stroke and healthcare cost savings among adult smokers if the menthol cigarette ban policy was implemented in NYC. We further calculated the reductions in the incidence of MI and stroke and associated healthcare costs across sex and racial and ethnic groups to examine the impact of the policy on health disparities in the long term.

Results

Table 1 reports the prevalence of usually smoked menthol cigarettes among adult smokers in NYC in 2018. There were about 880,000 adult smokers, among which approximately 431,000 (49%) usually smoked menthol cigarettes. About 44.1% of male smokers usually smoked menthol cigarettes, while the percentage was 59.3% among female smokers (p = 0.001). One-quarter (25.6%) of non-Latino White adults usually smoked menthol cigarettes, compared with 83.8% among non-Latino Black adults and 59.8% among Latino adults (p < 0.001 for both groups). In addition, adults who usually smoke menthol cigarettes were more likely to have lower educational attainment and household income compared to those who usually smoke non-menthol cigarettes. There were no significant differences in the
The prevalence of usual menthol cigarette smoking across different age groups.

Table 2 presents the projected number of MI and stroke events and healthcare costs among adults who smoke in NYC for the 20-year period. Under the status quo scenario (no menthol ban), the model estimated that there could be 57,232 (95% CI: 51,967–62,497) MI cases and 52,195 (47,446–56,945) stroke cases per 1 million adults who smoke in NYC by 2038. If a menthol cigarette ban policy was implemented in 2018, 2,862 MI cases and 1,983 stroke cases per 1 million adults could be averted by 2038. Our sensitivity analysis showed that, if the proportion of current menthol smokers who would quit under a menthol ban could increase to 50%, the averted cases of MI and stroke would be 8,115 and 5,762 per 1 million adults, respectively, by 2038 (Fig. 2). The model also projected that an average of $1,836 in healthcare costs per person could be saved among adults who smoke for the 20-year period due to the implementation of a menthol ban policy (Table 2). Given that the total number of adults who smoke was about 880,000 in NYC (Table 1), the total healthcare cost saving was estimated to be $1.62 billion.

| Table 1 Prevalence of usually smoked menthol cigarettes among NYC adults (18 +) smokers in 2018 (N = 880,000) |
|----------------------------------------------------------|-----------------|-----------------|--------------------|-----------------|
| Policy | Weighted n | % | 95% CI | P-value |
| No menthol ban | 31,000 | 48.5 | 32.3–65.1 | ref |
| Menthol ban | 194,000 | 50.3 | 43.7–56.9 | 0.850 |
| 45–64 | 181,000 | 55.0 | 48.7–61.2 | 0.487 |
| 65 and older | 25,000 | 36.0 | 26.4–46.8 | 0.217 |

| Table 2 Projected numbers of myocardial infarctions, strokes, and healthcare costs among NYC adult smokers, 2018–2038 |
|----------------------------------------------------------|-----------------|-----------------|-----------------|
| Policy | No. of MI, per million adults (95% CI) | Averted cases of MI, per million adults | No. of stroke, per million adults (95% CI) | Averted cases of stroke, per million adults | Healthcare costs, $ per person (95% CI) | Healthcare cost saving, $ per person |
| No menthol ban | 57,232 (51,967, 62,497) | — | 52,195 (47,446, 56,945) | — | 41,479 (37,622, 45,337) | — |
| Menthol ban | 54,370 (49,368, 59,372) | 2862 | 50,212 (45,643, 54,781) | 1983 | 39,643 (35,956, 43,330) | 1836 |
**Fig. 2** Projected cumulative averted cases of myocardial infarction and stroke in 20 years with different proportions of current menthol smokers who would quit under a menthol ban.

**Fig. 3** Projected reduction in incidence of cardiovascular diseases and healthcare costs by sex and race/ethnicity due to a potential menthol cigarette ban in NYC.
Figure 3 reports the projected reductions in the incidence of MI and stroke and savings in healthcare cost by sex and race and ethnicity. Non-Latino Black women were estimated to have the largest reductions in the incidence of MI and stroke, while White men were to have the least reductions in both incidences. Specifically, a potential menthol cigarette ban could reduce the incidence of MI by 7.81% among non-Latino Black women, 5.60% among Latino women, and 2.19% among non-Latino White women ($p<0.001$). The policy could reduce the incidence of MI by 7.34% among non-Latino Black men, 5.29% among Latino men, and 1.97% among non-Latino White men ($p<0.001$). The reduction in stroke incidence follows a similar pattern; the policy was projected to have a more significant impact on non-Latino Black and Latino adults and women compared to non-Latino White adults and men.

As for healthcare costs, the menthol cigarette ban policy could save an average of $2,855 per person among non-Latino Black women who smoke, $2,116 per person among Latino women who smoke, and $805 per person among non-Latino White women who smoke over 20 years. Among men, the healthcare savings were projected to be $2,709 per person among non-Latino Black adults who smoke, $1,961 per person among Latino adults who smoke, and $730 per person among non-Latino White adults who smoke. Sensitivity analysis on discount rate showed that a higher discount rate would result in less healthcare cost saving, though the overall impact across the tested range (i.e., 0–6%) was modest (results not shown in the figure).

Discussion

The results from our microsimulation model of the 20-year projected effects of a menthol smoking ban on CVD risk in NYC showed that the implementation of a menthol ban would result in an overall 5% reduction in MIs, a 3.8% reduction in stroke, and a cost savings of $1.62 billion over 20 years. The reduction in adverse outcomes projected by the model showed the most gains among women and particularly Black women. These results are consistent with other reports on the effect of menthol bans on health outcomes, [23] and our results project the implications of this policy on racial and ethnic disparities by 2038. To the best of our knowledge, our study is among the first to assess the impact of menthol ban policies on long-term health outcomes and disparities.

Regulatory policies to reduce smoking overall—including restrictions on advertising and smoking bans in workplaces and public spaces—have led to lower prevalence rates in smoking, but racial and ethnic disparities in menthol use persist. Menthol flavoring in cigarettes was first introduced in the late 1920s in the US, and concerted efforts by the tobacco industry have targeted women and Black communities to increase consumption among a previously low-smoking demographic. [14, 41] The result of this strategy was an increase in tobacco use among these groups in the ensuing years with a particular preference for menthol-flavored cigarettes, which is still present today. Recent studies show that menthol bans have led to a significant reduction in the sales of cigarettes and an increase in quit rates among usual and occasional menthol smokers. [22, 23] Promising results of menthol bans also show that racial and ethnic minorities report a higher rate of quitting among daily menthol smokers, [23] but barriers to uptake of evidence-based treatments remain.

Evidence-based treatments to reduce smoking have not been made accessible enough for low-income and minority groups. Racial and ethnic minority groups are particularly vulnerable to the risks of smoking, and uptake of protective strategies are less likely to be successful. [42, 43] Moreover, lack of recognition of sociocultural contexts in the implementation of social and policy interventions, including limited community engagement and collaboration with communities in developing policy interventions, may also be creating and/or exacerbating disparities. These need to be further examined and addressed to ensure that everyone in NYC has the opportunity to shape and benefit from these policy interventions.

This study has several limitations. First, like all simulation models, our model is a simplification of the real world and, thus, includes assumptions that may not be fully supported based on existing data. For example, we assumed that the menthol cigarette ban would only affect current menthol smokers rather than current non-menthol smokers or non-smokers. While a recent study has shown that the menthol cigarette ban may have negligible impact on current non-menthol smokers, [38] the policy impact on non-smokers (e.g., smoking initiation) is less clear.
and warrants further investigation. Also, we assumed that other health behaviors (e.g., diet, physical activity) would not change as simulated individuals age because introducing changes in other health behaviors would make it difficult for us to assess the effect of smoking on CVD. Second, we did not model the impact of smoking on non-CVD health outcomes such as lung cancer. Smoking is a risk factor for many diseases; it is impossible to model all of them. As a result, the projected health benefits and cost savings likely underestimated the other potential benefits of the menthol ban. Third, the CVD risk equations used in our microsimulation model did not include socioeconomic status (SES) such as education and income, which has been shown to be an important risk factor for CVD. [44] Thus, we were not able to model the impact of the menthol ban policy across different SES groups. More broadly, most existing CVD risk equations do not include SES. Further research should be done to incorporate SES into CVD risk equations, which will allow modeling researchers to examine the root causes of CVD health outcomes and health disparities. Additionally, our model was not able to assess the impact of a menthol ban on the number of cigarettes smoked per day or secondhand smoking due to the lack of related data and evidence. Both are important aspects related to a menthol ban and should be investigated in future epidemiological and modeling studies when new data become available. Finally, the policy environment is dynamic, and other local and federal legislations might be synergistic or antagonistic with a menthol ban. However, we were not able to capture these potential complex interactions between the menthol ban and other policies in the current study.

Conclusion

There is national support for a menthol cigarette sales ban. [45] The health cost of smoking-related illness in the US is approximately $300 billion, and smoking results in 480,000 deaths per year. [46] In NYC, the prevalence of menthol smoking among people who currently smoke is about 50% with the highest prevalence observed among non-Latino Black individuals (84%) and the lowest prevalence among non-Latino White individuals (26%). [36] Findings from our study show a reduction in CVD morbidity and an increase in related healthcare cost savings over a 20-year period with the implementation of a menthol ban in NYC. These results may be useful for policymakers that advocate for regulatory policies that limit access to cigarettes. Further, racial and ethnic minorities have been unfairly targeted by tobacco and advertising companies, likely contributing to the smoking-related health disparities seen across these groups. Results from this study thus would support a health equity agenda aimed at reducing health disparities in racialized populations.

Acknowledgements This study was conducted through the Marginalized Populations Health Data for New York City (HD4NYC) Working Group. HD4NYC, funded by the Robert Wood Johnson Foundation and led by the New York Academy of Medicine and the New York City Department of Health and Mental Hygiene, is a multi-institutional research platform that seeks to advance health equity by producing actionable, policy-relevant research and promoting the careers of academic and applied public health researchers. This study was also partially supported by a grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (R01HL141427). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Funding This study was conducted through the Marginalized Populations Health Data for New York City (HD4NYC) Working Group. HD4NYC, funded by the Robert Wood Johnson Foundation and led by the New York Academy of Medicine and the New York City Department of Health and Mental Hygiene, is a multi-institutional research platform that seeks to advance health equity by producing actionable, policy-relevant research and promoting the careers of academic and applied public health researchers. This study was also partially supported by a grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (R01HL141427). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Boyle P. Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Lung Cancer. 1997;17(1):1–60.

2. Thun MJ, Myers DG, Day-Lally C, et al. Age and the exposure-response relationships between cigarette smoking and premature death in Cancer Prevention Study II. Shopland Chang Cigar-Relat Dis Risks Their Implic Prev Control Natl Inst Health Bethesda Md. Published online 1997:383–413.

3. Control C for D, Prevention (CDC. Smoking-attributable mortality, years of potential life lost, and productivity losses–United States, 2000–2004. MMWR Morb Mortal Wkly Rep. 2008;57(45):1226.

4. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731–7.

5. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer. 2004;45:S3–9.

6. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMCPalmMed. 2011;11(1):36.

7. Villanti AC, Mowery PD, Delnevo CD, Niaura RS, Abrams DB, Giovino GA. Changes in the prevalence and correlates of menthol cigarette use in the USA, 2004–2014. Tob Control. 2016;25(Suppl 2):ii14–20.

8. Kuiper NM, Gammon D, Loomis B, et al. Trends in menthol and nonmenthol cigarette consumption in the United States during 2011–2015. Nicotine Tob Res. 2018;20(6):698–706.

9. Delnevo CD, Giovenco DP, Villanti AC. Assessment of menthol and nonmenthol cigarette consumption in the US, 2000 to 2018. JAMA Netw Open. 2020;3(8):e2013601–e2013601.

10. Smith PH, Assefa B, Kainth S, Salas-Ramirez KY, McKee SA, Giovino GA. Use of mentholated cigarettes and likelihood of smoking cessation in the United States: a meta-analysis. Nicotine Tob Res. 2020;22(3):307–16.

11. Mills SD, Hao Y, Ribisl KM, Wiesen CA, Hassmiller LK. The relationship between menthol cigarette use, smoking cessation, and relapse: findings from waves 1 to 4 of the population assessment of tobacco and health study. Nicotine Tob Res. 2021;23(6):966–75.

12. Stroud LR, Vergara-Lopez C, McCallum M, Gaffey AE, Corey A, Niaura R. High rates of menthol cigarette use among pregnant smokers: preliminary findings and call for future research. Nicotine Tob Res. 2020;22(10):1711–7.

13. Smith PH, Akpara E, Haq R, El-Miniawi M, Thompson AB. Gender and menthol cigarette use in the USA: a systematic review of the recent literature (2011–May 2017). Curr Addict Rep. 2017;4(4):431–8.

14. Anderson SJ. Marketing of menthol cigarettes and consumer perceptions: a review of tobacco industry documents. Tob Control. 2011;20(Suppl 2):ii20–8.

15. CDC. Smoking & Tobacco Use: Menthol and Cigarettes. Centers for disease control and prevention. https://www.cdc.gov/tobacco/basic_information/tobacco_industry/menthol-cigarettes/index.html. Accessed 5 Jan 2021.

16. Rock VJ, Davis SP, Thorne SL, Asman KJ, Caraballos R. Menthol cigarette use among racial and ethnic groups in the United States, 2004–2008. Nicotine Tob Res. 2010;12(suppl 2):S117–24.

17. Benowitz NL, Samet JM. The threat of menthol cigarettes to US public health. N Engl J Med. 2011;364(23):2179–81.

18. Delnevo CD, Ganz O, Goodwin RD. Banning menthol cigarettes: a social justice issue long overdue. Nicotine Tob Res. 2020;22(10):1673–5.

19. World Health Organization. Advisory note: banning menthol in tobacco products: WHO Study Group on Tobacco Product Regulation (TobReg). Published online 2016. https://escholarship.org/content/qt8td7w55n/qt8td7w55n.pdf. Accessed 5 Jan 2021.

20. Food and Drug Administration. Preliminary scientific evaluation of the possible public health effects of menthol versus nonmenthol cigarettes. Published online 2013. https://www.fda.gov/media/86497/download. Accessed 5 Jan 2021.

21. FDA. FDA commits to evidence-based actions aimed at saving lives and preventing future generations of smokers; 2021. https://www.fda.gov/news-events/press-announcements/fda-commits-evidence-based-actions-aimed-saving-lives-and-preventing-future-generations-smokers. Accessed 5 Jan 2021.

22. Chaiton M, Schwartz R, Shuldiner J, Tremblay G, Nugent R. Evaluating a real world ban on menthol cigarettes: an interrupted time-series analysis of sales. Nicotine Tob Res. 2020;22(4):576–9.

23. Chaiton MO, Nicoleau I, Schwartz R, et al. Ban on menthol-flavoured tobacco products predicts cigarette cessation at 1 year: a population cohort study. Tob Control. Published online 2019;tobaccocontrol-2018.

24. Chaiton M, Schwartz R, Cohen JE, Soule E, Eisenberg T. Association of Ontario’s ban on menthol cigarettes with smoking behavior 1 month after implementation. JAMA Intern Med. 2018;178(5):710–1.

25. Public Health and Tobacco Policy Center. NYC restriction on sale of flavored tobacco products. Public Health Advocacy Institute at Northeastern University School of Law; 2009. Accessed January 15, 2021. https://tobaccopolicycenter.org/tobacco-control/laws-of-new-york/nyc-flavored-tobacco-products/.

26. Legislative Research Center. Prohibiting the sale of flavored cigarettes. The New York City Council; 2019. Accessed January 15, 2021. https://legistar.council.nyc.gov/LegislationDetail.aspx?ID=3844813&GUID=29F2AB73-802D-4200-9F3B-C9A38DB78358&Options=ID

27. Henley SJ, Thomas CC, Sharapova SR, et al. Vital signs: disparities in tobacco-related cancer incidence and mortality—United States, 2004–2013. Morb Mortal Wkly Rep. 2016;65(44):1212–8.

28. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force
on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2019;74(10):e177–232.

29. Kanchi R, Perlman SE, Chernov C, et al. Gender and race disparities in cardiovascular disease risk factors among New York City adults: new York City Health and Nutrition Examination Survey (NYC HANES) 2013–2014. *J Urban Health.* 2018;95(6):801–12.

30. Centers for Disease Control and Prevention. *Health United States spotlight: racial and ethnic disparities in heart disease.* CDC; 2019. https://www.cdc.gov/nchs/hus/spotlight/HeartDiseaseSpotlight_2019_0404.pdf. Accessed 5 Jan 2021.

31. Rutter CM, Zaslavsky AM, Feuer EJ. Dynamic microsimulation models for health outcomes: a review. *Med Decis Making.* 2011;31(1):10–8.

32. Krijkamp EM, Alarid-Escudero F, Enns EA, Jalal HJ, Hunink MM, Pechlivanoglou P. Microsimulation modeling for health decision sciences using R: a tutorial. *Med Decis Making.* 2018;38(3):400–22.

33. Borschev A. The big book of simulation modeling: multimethod modeling with AnyLogic 6. Chicago: AnyLogic North America; 2013.

34. Thorpe LE, Greene C, Freeman A, et al. Rationale, design and respondent characteristics of the 2013–2014 New York City Health and Nutrition Examination Survey (NYC HANES 2013–2014). *Prev Med Rep.* 2015;2:580–5.

35. Zhang Y, Vittinghoff E, Fletcher MJ, et al. Associations of blood pressure and cholesterol levels during young adulthood with later cardiovascular events. *J Am Coll Cardiol.* 2019;74(3):330–41.

36. New York City Department of Health and Mental Hygiene. New York City Community Health Survey (CHS). Published 2018. Accessed July 14, 2019. https://www1.nyc.gov/site/doh/data/data-sets/community-health-survey.page

37. Bold KW, Jatlow P, Fucito LM, Eid T, Krishnan-Sarin S, O’Malley S. Evaluating the effect of switching to non-menthol cigarettes among current menthol smokers: an empirical study of a potential ban of characterising menthol flavour in cigarettes. *Tob Control.* 2020;29(6):624–30.

38. Levy DT, Cadham CJ, Sanchez-Romero LM, et al. An expert elicitation on the effects of a ban on menthol cigarettes and cigars in the United States. *Nicotine Tob Res.* 2021;23(11):1911–1920.

39. Jasani FS, Seixas AA, Madondo K, Li Y, Jean-Louis G, Pagán JA. Sleep duration and health care expenditures in the United States. *Med Care.* 2020;58(9):770–7.

40. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. *JAMA.* 2016;316(10):1093–103.

41. Gardiner PS. The African Americanization of menthol cigarette use in the United States. *Nicotine Tob Res.* 2004;6(Suppl_1):S55–65.

42. Lawrence D, Graber JE, Mills SL, Meissner HI, Warnecke R. Smoking cessation interventions in US racial/ethnic minority populations: an assessment of the literature. *Prev Med.* 2003;36(2):204–16.

43. Trinidad DR, Pérez-Stable EJ, White MM, Emery SL, Messer K. A nationwide analysis of US racial/ethnic disparities in smoking behaviors, smoking cessation, and cessation-related factors. *Am J Public Health.* 2011;101(4):699–706.

44. Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. *Nat Rev Cardiol.* 2009;6(11):712–22.

45. Czaplicki L, Schillo B, Rose SW, Zhou Y, Vallone D. National support for a menthol cigarette sales ban. *Public Health Rep.* Published online 2020:0033354920966004.

46. Health UD of, Services H. *The health consequences of smoking—50 years of progress: a report of the surgeon general.* Atlanta, GA: US Department of Health and Human Services, Centers for Disease …; 2014.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.